NCT04561258已完成1 期
Phase 1 Study to Evaluate the Safety of Genetically Modified, Autologous T Cells in Participants With HIV That is Well-Controlled on Antiretroviral Therapy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 4
- 主要终点
- Assess the safety of AGT103-T in HIV+ participants with well-controlled viremia on antiretroviral therapy: adverse events
研究概览
简要总结
This is a Phase 1 study to assess the safety of a gene and cell therapy for autologous donor lymphocyte infusion in HIV+ participants with well-controlled viremia on antiretroviral therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female between 18-60 years
- •Documented HIV infection for ≥3 years
- •Suppression of HIV to <50 copies of viral RNA/mL plasma for ≥2 years. Participants who had intermittent, isolated episodes of detectable low-level viremia (<500c/mL; blips) will remain eligible. Participant must have a complete antiretroviral treatment history including past and present data on resistance to antiretroviral therapy
- •Agree to continue their current antiretroviral regimen during the study period unless change in treatment with antiretroviral regimen is medically indicated
- •Have, in the Investigator's opinion, a fully active alternative antiretroviral regimen that can be used if resistance develops to the current antiretroviral therapy regimen
- •CD4 T cell count >400 cells/mm3
- •Has adequate organ function as indicated by the following laboratory values:
- •Hematocrit ≥33% or hemoglobin ≥13g/dL (males) and ≥12g/dL (females)
- •Platelet count ≥150,000/mm3
- •Absolute neutrophil count ≥1,500/mm3
- •Serum creatinine ≤1.3 times ULN or calculated creatinine clearance (for those with creatinine >1.3 ULN) ≥60mL/min
- •Prothrombin Time or INR ≤ 1.5 times ULN
- •Total bilirubin <1.5 times the ULN range. If total bilirubin is elevated, direct bilirubin must be < 2 times the ULN range, except in participants with Gilbert's Syndrome who must have serum bilirubin <3.0 times ULN (NOTE: If participant is on an atazanavir containing therapy then a direct bilirubin should be measured instead of the total bilirubin and must be ≤ 1.0mg/dL. Also, asymptomatic elevations due to ART medications are not exclusionary when, in the opinion of the Investigator, the abnormalities are not attributable to intrinsic hepatic disease).
- •Amylase < 3 times ULN at the time of screening
- •AST (SGOT) and ALT (SGPT): ≤ 3.0 times ULN
- •Adequate venous access, per Investigator judgement, and no other contraindications for leukapheresis
- •Weight (without shoes) ≥50 kilograms
- •Has the ability to understand the study and must be willing to comply with study-required procedures and visits
- •Written informed consent signed and dated by the study participant
- •A negative pregnancy test for females of childbearing potential. A female participant is considered to be of childbearing potential if she is menstruating, has an intact uterus and at least 1 ovary, and is less than 2 years postmenopausal.
- •Unless medically prescribed, a negative drug test for amphetamines; barbiturates; benzodiazepines; cocaine; methadone (Dolophine®); opiates (codeine, morphine only); phencyclidine (PCP); propoxyphene
- •Agree to participate in the 15-year Long-Term Follow-Up study
排除标准
- •Active viral hepatitis B or hepatitis C infection. A complete hepatitis B virus (HBV) screen (B-core antibody, HBV surface antibody, and HBV surface antigen testing) must be completed. Viral load testing will be used in questionable cases, per the discretion of the Investigator.
- •The results for hepatitis B may be positive for surface antibodies against HBV but must be negative for circulating HBV surface antigen to confirm the absence of active infection and negative for HBV core antigen to excluded previous active hepatitis
- •The results for hepatitis C virus (HCV) may be positive for antibodies against HCV but must be negative for HCV viral RNA in blood to confirm the absence of active infection.
- •Liver disease by any cause
- •Active or history (within 5 years prior to screening) of at least one acquired immune deficiency syndrome (AIDS)-defining complication
- •CD4 T cell nadir of <200 cells/mm3, if the information is available at the time of screening per medical records. If this information is unavailable, the Investigator will document this in the study source records
- •Cancer or malignancy that has not been in remission for at least 5 years prior to screening, with the exception of successfully treated basal cell carcinoma of the skin
- •Current diagnosis of congestive heart failure, uncontrolled angina, or arrhythmias
- •Baseline prolonged QTc (Fridericia Formula) of 450 ms or more
- •Any clinically significant renal, hepatic, or pulmonary disease
- •History of active or latent tuberculosis, regardless of treatment history
- •Received high dose cytoreduction therapy within 3 months prior to screening
- •Currently taking (or has taken within 6 months prior to screening) the antiretroviral drug Selzentry (Maraviroc)
- •Currently using protease inhibitors, efavirenz, or zidovudine
- •Prior events of hemorrhagic cystitis
- •Evidence of urinary outflow obstruction by history, enlarged prostate on physical exam, or use of medications for urinary outflow obstruction
- •Is being treated for culture-confirmed bacteremia or had culture-confirmed bacteremia within 1 month prior to screening
- •Has signs or symptoms of acute infectious disease
- •History of hereditary angioedema, acquired angioedema, or idiopathic angioedema
- •History of neurological diseases
- •Significant laboratory values and/or chronic medical condition that in the opinion of the Investigator could impact trial participation
- •Received another investigational drug or device within 30 days of screening
- •Previously received any gene transfer therapy
- •History or any features on physical examination indicative of a bleeding diathesis
- •Use of aspirin, dipyridamole, warfarin and antithrombin inhibitors or any other medication that is likely to affect platelet function or other aspects of blood coagulation within 3 days prior to the Leukapheresis Visit
- •Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g., monoclonal antibodies, interleukin-2, interferon-alpha or gamma, granulocyte colony stimulating factors, etc.) within 30 days prior to screening (NOTE: Use of inhaled or topical steroids is not exclusionary)
- •Currently pregnant or breast-feeding
- •Unwilling to use acceptable methods of birth control for 6 months following the infusion of AGT103-T if sexually active with opposite sex. The following are acceptable methods of birth control: condoms (male or female) with or without a spermicidal agent, intrauterine device, diaphragm or cervical cap with spermicide, or hormonal-based contraception
- •Active alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirements
- •Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to screening
- •Recent vaccination or intercurrent illness within 5 weeks prior to screening (NOTE: It is recommended that participants should have completed their routine vaccinations, e.g., hepatitis A or B, pneumococcus, influenza and tetanus diphtheria booster, at least 5 weeks prior to screening for the study)
- •Known allergy to Dimethyl Sulfoxide (DMSO)
- •Known allergy to Cyclophosphamide
结局指标
主要结局
Assess the safety of AGT103-T in HIV+ participants with well-controlled viremia on antiretroviral therapy: adverse events
时间窗: Days 1 to 180 post-infusion
Incidence of adverse events related to AGT103-T will be graded using NCI CTCAE (v5.0)
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Pulmonary Hypertension: Assessment of Cell TherapyHypertension, PulmonaryNCT00469027Northern Therapeutics7
已完成
1 期
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaB-cell Chronic Lymphocytic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaSplenic Marginal Zone LymphomaWaldenström MacroglobulinemiaNCT00621452Fred Hutchinson Cancer Center12
进行中（未招募）
1 期
Transfer of Genetically Engineered Lymphocytes in Melanoma PatientsMelanomaNCT01586403Loyola University14
撤回
1 期
Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress SyndromeCovid19Acute Respiratory Distress SyndromeNCT04737161Stanford University
已完成
1 期
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent PorphyriaAcute Intermittent PorphyriaNCT02082860Digna Biotech S.L.8